CTSO
Income statement / Annual
Last year (2024), Cytosorbents Corporation's total revenue was $35.59 M,
a decrease of 2.08% from the previous year.
In 2024, Cytosorbents Corporation's net income was -$20.72 M.
See Cytosorbents Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$35.59 M |
$36.35 M |
$29.36 M |
$40.11 M |
$39.45 M |
$22.77 M |
$20.25 M |
$13.38 M |
$8.21 M |
$4.06 M |
| Cost of Revenue |
$10.47 M
|
$13.96 M
|
$13.96 M
|
$11.05 M
|
$11.05 M
|
$7.36 M
|
$7.49 M
|
$5.52 M
|
$3.95 M
|
$2.21 M
|
| Gross Profit |
$25.13 M
|
$22.39 M
|
$15.40 M
|
$29.06 M
|
$28.40 M
|
$15.40 M
|
$12.76 M
|
$7.86 M
|
$4.25 M
|
$1.84 M
|
| Gross Profit Ratio |
0.71
|
0.62
|
0.52
|
0.72
|
0.72
|
0.68
|
0.63
|
0.59
|
0.52
|
0.45
|
| Research and Development Expenses |
$6.92 M
|
$15.73 M
|
$15.12 M
|
$16.38 M
|
$8.81 M
|
$12.09 M
|
$7.72 M
|
$4.05 M
|
$4.78 M
|
$3.87 M
|
| General & Administrative Expenses |
$0.00
|
$37.87 M
|
$37.14 M
|
$38.48 M
|
$31.51 M
|
$24.47 M
|
$22.88 M
|
$15.43 M
|
$12.28 M
|
$8.01 M
|
| Selling & Marketing Expenses |
$0.00
|
-$936,000.00
|
$582,000.00
|
$615,000.00
|
$285,000.00
|
$314,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$35.00 M
|
$36.94 M
|
$37.14 M
|
$38.48 M
|
$31.51 M
|
$24.47 M
|
$22.88 M
|
$15.43 M
|
$12.28 M
|
$8.01 M
|
| Other Expenses |
$0.00
|
$936,000.00
|
-$5.33 M
|
-$3.06 M
|
-$1.55 M
|
-$2.18 M
|
-$2.25 M
|
-$1.77 M
|
-$1.32 M
|
-$735,863.00
|
| Operating Expenses |
$41.91 M
|
$53.60 M
|
$46.93 M
|
$51.81 M
|
$38.77 M
|
$34.38 M
|
$28.35 M
|
$17.71 M
|
$15.74 M
|
$11.15 M
|
| Cost And Expenses |
$52.38 M
|
$67.56 M
|
$60.88 M
|
$62.85 M
|
$49.82 M
|
$41.74 M
|
$35.84 M
|
$23.22 M
|
$19.70 M
|
$13.36 M
|
| Interest Income |
$0.00
|
$0.00
|
$133,000.00
|
$28,000.00
|
$1.20 M
|
$1.03 M
|
$0.00
|
$0.00
|
$0.00
|
$18,602.00
|
| Interest Expense |
$1.40 M
|
$157,891.00
|
$132,597.00
|
$0.00
|
$1.20 M
|
$1.03 M
|
$1.46 M
|
$749,076.00
|
$231,804.00
|
$9,301.00
|
| Depreciation & Amortization |
$1.74 M
|
$2.03 M
|
$1.13 M
|
$1.13 M
|
$660,788.00
|
$581,532.00
|
$390,551.00
|
$218,271.00
|
$161,613.00
|
$112,969.00
|
| EBITDA |
-$19.26 M |
-$29.18 M |
-$30.00 M |
-$22.01 M |
-$9.71 M |
-$18.74 M |
-$15.98 M |
-$8.17 M |
-$11.86 M |
-$9.19 M |
| EBITDA Ratio |
-0.54
|
-0.8
|
-1.02
|
-0.55
|
-0.25
|
-0.82
|
-0.79
|
-0.61
|
-1.45
|
-2.27
|
| Operating Income Ratio |
-0.47
|
-0.86
|
-1.07
|
-0.57
|
-0.26
|
-0.83
|
-0.77
|
-0.74
|
-1.4
|
-2.29
|
| Total Other Income/Expenses Net |
-$5.62 M
|
$1.89 M
|
-$2.38 M
|
-$2.55 M
|
$1.41 M
|
-$1.38 M
|
-$2.25 M
|
$705,060.00
|
-$589,881.00
|
$847,315.00
|
| Income Before Tax |
-$22.41 M
|
-$29.32 M
|
-$33.91 M
|
-$25.30 M
|
-$8.96 M
|
-$20.36 M
|
-$17.83 M
|
-$9.14 M
|
-$12.26 M
|
-$8.46 M
|
| Income Before Tax Ratio |
-0.63
|
-0.81
|
-1.15
|
-0.63
|
-0.23
|
-0.89
|
-0.88
|
-0.68
|
-1.49
|
-2.09
|
| Income Tax Expense |
-$1.69 M
|
-$813,739.00
|
-$1.09 M
|
-$736,000.00
|
-$1.13 M
|
-$1.09 M
|
-$619,546.00
|
-$676,739.00
|
-$318,550.00
|
-$324,606.00
|
| Net Income |
-$20.72 M
|
-$28.51 M
|
-$32.81 M
|
-$24.56 M
|
-$7.84 M
|
-$19.27 M
|
-$17.21 M
|
-$8.46 M
|
-$11.94 M
|
-$8.13 M
|
| Net Income Ratio |
-0.58
|
-0.78
|
-1.12
|
-0.61
|
-0.2
|
-0.85
|
-0.85
|
-0.63
|
-1.45
|
-2
|
| EPS |
-0.38 |
-0.64 |
-0.75 |
-0.57 |
-0.2 |
-0.6 |
-0.56 |
-0.31 |
-0.47 |
-0.33 |
| EPS Diluted |
-0.38 |
-0.64 |
-0.75 |
-0.57 |
-0.2 |
-0.6 |
-0.56 |
-0.31 |
-0.47 |
-0.33 |
| Weighted Average Shares Out |
$54.43 M
|
$44.66 M
|
$43.57 M
|
$43.36 M
|
$38.82 M
|
$32.26 M
|
$30.72 M
|
$27.61 M
|
$25.43 M
|
$24.89 M
|
| Weighted Average Shares Out Diluted |
$54.43 M
|
$44.66 M
|
$43.57 M
|
$43.36 M
|
$38.82 M
|
$32.26 M
|
$30.72 M
|
$27.61 M
|
$25.43 M
|
$24.89 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
